N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.
PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR
申请人:Abbott GmbH & Co. KG
公开号:EP2089003A1
公开(公告)日:2009-08-19
CRYSTALLINE CHEMOTHERAPEUTIC
申请人:AbbVie Bahamas Ltd.
公开号:EP2195300B1
公开(公告)日:2015-06-24
Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
申请人:Steinberg Joyce L.
公开号:US20090203709A1
公开(公告)日:2009-08-13
A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.